Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...

Jose Sanchez, who was paralyzed from the chest down in a 2022 shooting, is learning to walk again. Sanchez is using a computerized C-brace that utilizes AI to analyze his gait and adjust tension. His ...